1
|
Munir F, Javaid HW, Rana MBM, Shaukat F. Ceftriaxone-Induced Reversible Agranulocytosis: A Case Report and Review of Drug-Induced Agranulocytosis. Cureus 2022; 14:e23226. [PMID: 35449634 PMCID: PMC9012477 DOI: 10.7759/cureus.23226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/16/2022] [Indexed: 11/05/2022] Open
Abstract
In the modern era of medicine, agranulocytosis is a rare occurrence. Despite significant improvement in patient survival, it still carries significant mortality. Agranulocytosis is most commonly caused by chemotherapeutic agents and numerous non-chemo drugs. As it can develop anytime during treatment and patients can remain asymptomatic, frequent cell count monitoring is an essential tool to make a timely diagnosis. An appropriate drug switch, work up to rule out infection and granulocyte colony-stimulating factor (G-CSF) injection in high-risk cases is the management. The patient should be kept under observation till the resolution of agranulocytosis. We present a case of ceftriaxone-induced agranulocytosis which was completely reversible upon stoppage of drug and granulocyte colony-stimulating factor administration. The pathogenesis of ceftriaxone-induced agranulocytosis is unknown. It is suggested to occur either by an immunologic mechanism or because of direct drug toxicity.
Collapse
|
2
|
Pan Y, Liu B, Liu J, Zhuang W, He Q, Lan M. Clopidogrel-induced neutropenia in an 80-year-old patient with chronic kidney disease who underwent percutaneous coronary intervention: a case report and literature review. BMC Cardiovasc Disord 2022; 22:40. [PMID: 35148681 PMCID: PMC8832855 DOI: 10.1186/s12872-022-02490-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Accepted: 02/03/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Clopidogrel is a widely-used antiplatelet and acts as an adenosine diphosphate receptor inhibitor. Neutropenia is a rare but serious adverse effect of clopidogrel. It is unknown whether this adverse effect has any association with impaired kidney function. CASE PRESENTATION An 80-year-old male with chronic kidney disease was diagnosed with non-ST elevation myocardial infarction and underwent percutaneous coronary intervention. During hospitalization, the patient was diagnosed with contrast-induced nephropathy, treated symptomatically, and discharged with a back-to-baseline creatinine level. Two weeks later, the patient presented to the emergency department with fever and chills. Complete blood count showed leukopenia (0.84 × 103/mm3) and severe neutropenia (0.13 × 103/mm3). Blood cultures were positive for Pseudomonas aeruginosa. Clopidogrel was stopped immediately and switched into ticagrelor. Imipenem and granulocyte colony-stimulating factor were administered to the patient. The patient's white blood cell and absolute neutrophil count were within the normal range after four days of treatment. The patient was discharged after a 10-day hospitalization, and his complete blood counts were normal during further follow-ups. CONCLUSIONS Clopidogrel was the most likely primary cause of neutropenia in our case. The incidence of clopidogrel-induced neutropenia is low and the exact mechanism is not fully explained. We provide suggestions on the management of clopidogrel-associated neutropenia, and summarize all five cases of clopidogrel-induced neutropenia in patients with impaired kidney function.
Collapse
Affiliation(s)
- Yannan Pan
- School of Medicine, Peking University Health Science Center, Beijing, China
| | - Bing Liu
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China
| | - Junmeng Liu
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China
| | - Wei Zhuang
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Qing He
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China.
| | - Ming Lan
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China.
| |
Collapse
|
3
|
Holz JM, Chevtchenko AV, Aitullina A. Acute antibiotically induced neutropenia: A systematic review of case reports. Br J Clin Pharmacol 2021; 88:1978-1984. [PMID: 34897762 DOI: 10.1111/bcp.15170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 10/20/2021] [Accepted: 11/21/2021] [Indexed: 11/27/2022] Open
Abstract
AIMS Acute neutropenia induced by antibiotics is a rare side effect of this frequently prescribed class of drugs. We aim to find similarities and differences between reported cases. METHODS Through a database search (PubMed, 1968-2020), we identified published case reports and extracted, among other data, patient demographics, duration of treatment with the respective agent, and duration of recovery. RESULTS Overall, 83 cases were included. Neutropenia developed after a median (min-max) of 21 (17.5-28.5) days of treatment and was resolved after a median (min-max) of 6 (3.0-8.75) days. Vancomycin and ceftaroline emerged as the two most commonly described antibiotics. In 51.8% of cases, the suspected antibiotic was discontinued; in 37.4% of cases, it was substituted by another agent. Only three case reports mentioned death as a result of neutropenia. The use of granulocyte colony-stimulating growth factors (CSFs) shortened the duration of neutropenia and improved outcome for patients' health. CONCLUSION Neutropenia induced by antibiotics remains a rare or rarely reported side effect. Long-term and high-dose treatment regimens expose a higher risk of development. Thus, regular full blood counts are advised during therapy.
Collapse
Affiliation(s)
- Julian M Holz
- Faculty of Medicine, Riga Stradins University, Riga, Latvia
| | | | - Aleksandra Aitullina
- Department of Pharmacology, Paul Stradins Clinical University Hospital, Riga Stradins University, Riga, Latvia
| |
Collapse
|
4
|
Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients. J Clin Med 2020; 9:jcm9061808. [PMID: 32531979 PMCID: PMC7356965 DOI: 10.3390/jcm9061808] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 06/03/2020] [Accepted: 06/08/2020] [Indexed: 02/07/2023] Open
Abstract
Agranulocytosis is a rare, but serious and life-threatening hematologic disorder in elderly patients. Idiosyncratic drug-induced agranulocytosis (IDIA) has been classically defined by a neutrophil count below 0.5 × 109/L. The annual incidence of IDIA in Europe is about 1.6–9.2 cases per million inhabitants. Increasing age and female sex have been considered as risk factors for the development of this condition. Besides, it is well known that older people take on average more drugs than younger people. This condition is most often associated with the intake of antibacterial agents, antiplatelets, antithyroids, antipsychotics, antiepileptics and nonsteroidal anti-inflammatory drugs (NSAIDs). Initially, agranulocytosis may present without symptoms, but may quickly progress to a severe infection and sepsis. The causative drug should be immediately stopped. In febrile patients, blood cultures and where indicated, site-specific cultures should be obtained and early treatment with empirical broad-spectrum antibiotics started. Even with adequate treatment, the mortality rate is higher in elderly patients reaching up to 20%. Hematopoietic growth factors have proven to be useful as they shorten the duration of neutropenia. However, data on neutropenia and agranulocytosis in the elderly meeting the criteria of evidence-based medicine are still poor in the literature. This review analyzes the results of our experience as well as other published studies of the universal literature.
Collapse
|
5
|
Andrès E, Lorenzo-Villalba N, Mourot-Cottet R, Maloisel F, Tebacher M, Gottenberg JE, Goichot B, Herbrecht R, Zulfiqar AA. Severe Neutropenia and Agranulocytosis Related to Antithyroid Drugs: A Study of 30 Cases Managed in A Single Reference Center. MEDICINES (BASEL, SWITZERLAND) 2020; 7:E15. [PMID: 32204561 PMCID: PMC7151575 DOI: 10.3390/medicines7030015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 03/14/2020] [Accepted: 03/16/2020] [Indexed: 11/16/2022]
Abstract
BACKGROUND The most important series devoted to antithyroid drug-induced severe neutropenia and agranulocytosis are Japanese studies, almost specifically in relation to the intake of methimazole. The clinical data of 30 Caucasian patients followed up for antithyroid drug-induced neutropenia at a third-level hospital are reported. Methods: The data of 30 patients with idiosyncratic antithyroid drug-induced neutropenia and agranulocytosis from a cohort study on drug-induced neutropenia and agranulocytosis conducted at the University Hospital of Strasbourg (France) were retrospectively reviewed. Results: The mean patient age was 61.7 years old (range: 20-87), and the gender ratio (F/M) was 4. Several comorbidities were reported in 23 patients (76.7%), with the mean Charlson comorbidity index of 1. The causative drugs were carbimazole and benzylthiouracil, in 28 (93.3%) and 2 cases, respectively, prescribed primarily for multi-hetero-nodular goiter or thyroid nodule to 18 patients (60%). Sore throat and acute tonsillitis (40%), isolated fever (20%), septicemia (13.3%), documented pneumonia (6.7%), and septic shock (6.7%) were the main clinical features upon admission. The mean neutrophil count at nadir was 0.02 and 0 × 109/L (range: 0-0.3). Regarding the patients' hospital course: 13 cases (43.3%) worsened during hospitalization, severe sepsis was found in 26.7%, systemic inflammatory response syndrome-in 13.3%, and septic shock-in 3.3% of the cases, respectively. Broad-spectrum antibiotics were indicated for all the patients, and 21 (73.3%) of them received hematopoietic growth factors. Hematological recovery (neutrophil count ≥ 1.5 × 109/L) was seen at 8.3 days (range: 2-24), but faster in those receiving hematopoietic growth factors (4.9 days, p = 0.046). Two patients died during hospitalization, and the rest had a favorable clinical outcome. Conclusions: Antithyroid drug-induced neutropenia represents a serious complication resulting from the rates of severe infections especially in those cases severe neutropenia. In this setting, an established procedure for the management of patients seems useful or even indispensable in view of potential mortality.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Departments of Internal Medicine, Strasbourg University Hospitals, 67000 Strasbourg, France; (N.L.-V.); (R.M.-C.); (B.G.); (A.-A.Z.)
| | - Noel Lorenzo-Villalba
- Departments of Internal Medicine, Strasbourg University Hospitals, 67000 Strasbourg, France; (N.L.-V.); (R.M.-C.); (B.G.); (A.-A.Z.)
| | - Rachel Mourot-Cottet
- Departments of Internal Medicine, Strasbourg University Hospitals, 67000 Strasbourg, France; (N.L.-V.); (R.M.-C.); (B.G.); (A.-A.Z.)
| | - Frédéric Maloisel
- Onco-Hematology, Strasbourg University Hospitals, 67000 Strasbourg, France; (F.M.); (R.H.)
| | - Martine Tebacher
- Regional Pharmacovigilance Centre of Alsace, 67000 Strasbourg, France;
| | | | - Bernard Goichot
- Departments of Internal Medicine, Strasbourg University Hospitals, 67000 Strasbourg, France; (N.L.-V.); (R.M.-C.); (B.G.); (A.-A.Z.)
| | - Raoul Herbrecht
- Onco-Hematology, Strasbourg University Hospitals, 67000 Strasbourg, France; (F.M.); (R.H.)
| | - Abrar-Ahmad Zulfiqar
- Departments of Internal Medicine, Strasbourg University Hospitals, 67000 Strasbourg, France; (N.L.-V.); (R.M.-C.); (B.G.); (A.-A.Z.)
| |
Collapse
|
6
|
Andrès E, Villalba NL, Zulfiqar AA, Serraj K, Mourot-Cottet R, Gottenberg AJE. State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies. J Clin Med 2019; 8:jcm8091351. [PMID: 31480527 PMCID: PMC6788182 DOI: 10.3390/jcm8091351] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2019] [Revised: 08/29/2019] [Accepted: 08/29/2019] [Indexed: 02/06/2023] Open
Abstract
INTRODUCTION Idiosyncratic drug-induced neutropenia and agranulocytosis is seldom discussed in the literature, especially for new drugs such as biotherapies outside the context of oncology. In the present paper, we report and discuss the clinical data and management of this relatively rare disorder, with a focus on biotherapies used in autoimmune and auto-inflammatory diseases. MATERIALS AND METHODS A review of the literature was carried out using the PubMed database of the US National Library of Medicine. We searched for articles published between January 2010 and May 2019 using the following key words or associations: "drug-induced neutropenia", "drug-induced agranulocytosis", and "idiosyncratic agranulocytosis". We included specific searches on several biotherapies used outside the context of oncology, including: tumor necrosis factor (TNF)-alpha inhibitors, anti-CD20 agents, anti-C52 agents, interleukin (IL) 6 inhibitors, IL 1 inhibitors, and B-cell activating factor inhibitor. RESULTS Idiosyncratic neutropenia remains a potentially serious adverse event due to the frequency of severe sepsis with severe deep tissue infections (e.g., pneumonia), septicemia, and septic shock in approximately two-thirds of all hospitalized patients with grade 3 or 4 neutropenia (neutrophil count (NC) ≤ 0.5 × 109/L and ≤ 0.1 × 109/L, respectively). Over the last 20 years, several drugs have been strongly associated with the occurrence of idiosyncratic neutropenia, including antithyroid drugs, ticlopidine, clozapine, sulfasalazine, antibiotics such as trimethoprim-sulfamethoxazole, and deferiprone. Transient grade 1-2 neutropenia (absolute blood NC between 1.5 and 0.5 × 109/L) related to biotherapy is relatively common with these drugs. An approximate 10% prevalence of such neutropenia has been reported with several of these biotherapies (e.g., TNF-alpha inhibitors, IL6 inhibitors, and anti-CD52 agents). Grade 3-4 neutropenia or agranulocytosis and clinical manifestations related to sepsis are less common, with only a few case reports to date for most biotherapies. Special mention should be made of late onset and potentially severe neutropenia, especially following anti-CD52 agent therapy. During drug therapy, several prognostic factors have been identified that may be helpful when identifying 'susceptible' patients. Older age (>65 years), septicemia or shock, renal failure, and a neutrophil count ≤0.1 × 109/L have been identified as poor prognostic factors. Idiosyncratic neutropenia should be managed depending on clinical severity, with permanent/transient discontinuation or a lower dose of the drug, switching from one drug to another of the same or another class, broad-spectrum antibiotics in cases of sepsis, and hematopoietic growth factors (particularly G-CSF). CONCLUSION Significant progress has been made in recent years in the field of idiosyncratic drug-induced neutropenia, leading to an improvement in their prognosis (currently, mortality rate between 5 and 10%). Clinicians must continue their efforts to improve their knowledge of these adverse events with new drugs as biotherapies.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine, Medical Clinic B, University Hospital of Strasbourg, 67084 Strasbourg, France.
| | - Noel Lorenzo Villalba
- Department of Internal Medicine, Medical Clinic B, University Hospital of Strasbourg, 67084 Strasbourg, France
| | - Abrar-Ahmad Zulfiqar
- Department of Internal Medicine, Medical Clinic B, University Hospital of Strasbourg, 67084 Strasbourg, France
| | - Khalid Serraj
- Departments of Internal Medicine, University Hospital of Oujda, 59000 Oujda, Morocco
| | - Rachel Mourot-Cottet
- Department of Internal Medicine, Medical Clinic B, University Hospital of Strasbourg, 67084 Strasbourg, France
| | - And Jacques-Eric Gottenberg
- Department of Rheumatology, University Hospital of Strasbourg, 67084 Strasbourg, France
- Referral Center of Immune Cytopenias, University Hospital of Strasbourg, 67084 Strasbourg, France
| |
Collapse
|
7
|
Rudin D, Lanzilotto A, Bachmann F, Housecroft CE, Constable EC, Drewe J, Haschke M, Krähenbühl S. Non-immunological toxicological mechanisms of metamizole-associated neutropenia in HL60 cells. Biochem Pharmacol 2019; 163:345-356. [PMID: 30653950 DOI: 10.1016/j.bcp.2019.01.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 01/11/2019] [Indexed: 01/15/2023]
Abstract
Metamizole is an analgesic and antipyretic, but can cause neutropenia and agranulocytosis. We investigated the toxicity of the metabolites N-methyl-4-aminoantipyrine (MAA), 4-aminoantipyrine (AA), N-formyl-4-aminoantipyrine (FAA) and N-acetyl-4-aminoantipyrine (AAA) on neutrophil granulocytes and on HL60 cells (granulocyte precursor cell line). MAA, FAA, AA, and AAA (up to 100 µM) alone were not toxic for HL60 cells or granulocytes. In the presence of the myeloperoxidase substrate H2O2, MAA reduced cytotoxicity for HL60 cells at low concentrations (<50 µM), but increased cytotoxicity at 100 µM H2O2. Neutrophil granulocytes were resistant to H2O2 and MAA. Fe2+ and Fe3+ were not toxic to HL60 cells, irrespective of the presence of H2O2 and MAA. Similarly, MAA did not increase the toxicity of lactoferrin, hemoglobin or methemoglobin for HL60 cells. Hemin (hemoglobin degradation product containing a porphyrin ring and Fe3+) was toxic on HL60 cells and cytotoxicity was increased by MAA. EDTA, N-acetylcystein and glutathione prevented the toxicity of hemin and hemin/MAA. The absorption spectrum of hemin changed concentration-dependently after addition of MAA, suggesting an interaction between Fe3+ and MAA. NMR revealed the formation of a stable MAA reaction product with a reaction pathway involving the formation of an electrophilic intermediate. In conclusion, MAA, the principle metabolite of metamizole, increased cytotoxicity of hemin by a reaction involving the formation of an electrophilic metabolite. Accordingly, cytotoxicity of MAA/hemin could be prevented by the iron chelator EDTA and by the electron donors NAC and glutathione. Situations with increased production of hemin may represent a risk factor for metamizole-associated granulocytopenia.
Collapse
Affiliation(s)
- Deborah Rudin
- Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland; Department of Biomedicine, University of Basel, Switzerland
| | | | - Fabio Bachmann
- Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland; Department of Biomedicine, University of Basel, Switzerland
| | | | | | - Jürgen Drewe
- Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland
| | - Manuel Haschke
- Division of Clinical Pharmacology & Toxicology, Inselspital, Bern, Switzerland
| | - Stephan Krähenbühl
- Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland; Department of Biomedicine, University of Basel, Switzerland; Swiss Centre of Applied Human Toxicology (SCAHT), Basel, Switzerland.
| |
Collapse
|
8
|
Andrès E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg JE. History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort. Eur J Intern Med 2017; 46:e13-e14. [PMID: 28823525 DOI: 10.1016/j.ejim.2017.08.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Accepted: 08/15/2017] [Indexed: 11/25/2022]
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine, Strasbourg University Hospitals, France.
| | | | - Frédéric Maloisel
- Department of Onco-hematology, Strasbourg University Hospitals, France
| | - Thomas Vogel
- Department of Geriatrics, Strasbourg University Hospital, France
| | | | | |
Collapse
|
9
|
Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R. History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. J Clin Med 2017; 6:E92. [PMID: 28954408 PMCID: PMC5664007 DOI: 10.3390/jcm6100092] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2017] [Revised: 09/14/2017] [Accepted: 09/16/2017] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Despite major advances in its prevention and treatment, febrile neutropenia remains a most concerning complication of cancer chemotherapy. Outside the oncology setting, however, only few data are currently available on febrile neutropenia related to non-chemotherapy drugs. We report here data on 76 patients with febrile neutropenia related to non-chemotherapy drugs, followed up in a referral center within a university hospital. PATIENTS AND METHODS Data from 76 patients with idiosyncratic drug-induced febrile neutropenia were retrospectively reviewed. All cases were extracted from a cohort study on agranulocytosis conducted at the Strasbourg University Hospital (Strasbourg, France). RESULTS Mean patient age was 52.2 years old (range: 18-93) and gender ratio (F/M) 1.6, with several comorbidities present in 86.8% of patients. The most common causative drugs were: antibiotics (37.4%), antithyroid drugs (17.2%), neuroleptic and anti-epileptic agents (13.1%), non-steroidal anti-inflammatory agents and analgesics (8%), and platelet aggregation inhibitors (8%). Main clinical presentations upon hospitalization included isolated fever (30%), sore throat, acute tonsillitis and sinusitis (18.4%), documented pneumonia (18.4%), septicemia (14.5%), and septic shock (6.6%). Mean neutrophil count at nadir was 0.13 × 10(9)/L (range: 0-0.48). While in hospital, 22 patients (28.9%) worsened clinically and required intensive care unit placement. All patients were promptly treated with broad-spectrum antibiotics, and 45 (59.2%) with hematopoietic growth factors. Mean duration of hematological recovery (neutrophil count ≥1.5 × 10(9)/L) was 7.5 days (range: 2-21), which was reduced to 0.7 days (range: 2-16) (p = 0.089) with hematopoietic growth factors. Outcome was favorable in 89.5% of patients, whereas eight died. CONCLUSIONS Like in oncology and myelosuppressive chemotherapy settings, idiosyncratic febrile neutropenia is typically serious, about 40% of patients exhibiting severe pneumonia, septicemia, and septic shock, with a mortality rate of 10%. Like in febrile, chemotherapy-related neutropenia, modern and timely management (immediate broad spectrum antibiotherapy, hematopoietic growth factors) may reduce infection-related mortality. All practitioners should be aware of this potential side-effect that may even occur in the event of "daily medication" exposure.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Departments of Internal, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Rachel Mourot-Cottet
- Departments of Internal, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Frédéric Maloisel
- Departments of Onco-hematology, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Olivier Keller
- Departments of Internal, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Thomas Vogel
- Departments of Geriatrics, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - François Séverac
- Departments of Statistics, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Martine Tebacher
- Regional Pharmacovigilance Centre of Alsace, Strasbourg 67000, France.
| | | | | | - Georges Kaltenbach
- Departments of Geriatrics, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Bernard Goichot
- Departments of Internal, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Jean Sibilia
- Departments of Rheumatology, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Anne-Sophie Korganow
- Departments of Internal, Strasbourg University Hospitals, Strasbourg 67000, France.
| | - Raoul Herbrecht
- Departments of Onco-hematology, Strasbourg University Hospitals, Strasbourg 67000, France.
| |
Collapse
|
10
|
Abstract
INTRODUCTION To date, non-chemotherapy drug-induced severe neutropenia (neutrophil count of ≤0.5 x 109/L) also called idiosyncratic drug-induced agranulocytosis is little discussed in the literature. In the present paper, we report and discuss the clinical data and management of this rare disorder. Areas covered: To do this, we carried out a review of the literature using PubMed database of the US National Library of Medicine. We also used data from the American Society of Hematology educational books, textbooks of Hematology and Internal medicine, and information gleaned from international meetings. Expert opinion: Idiosyncratic agranulocytosis remains a potentially serious adverse event due to the frequency of severe sepsis with severe deep tissue infections (e.g., pneumonia), septicemia, and septic shock in approximately two-thirds of all hospitalized patients. In this context, several prognostic factors have been identified that may be helpful when identifying 'susceptible' patients. Old age (>65 years), septicemia or shock, renal failure, and a neutrophil count ≤0.1 × 109/L have been consensually accepted as poor prognostic factors. In our experience, modern management with pre-established procedures, intravenous broad-spectrum antibiotics and hematopoietic growth factors (particularly G-CSF) is likely to improve the prognosis. Thus with appropriate management, the mortality rate is currently between 5 to 10%.
Collapse
Affiliation(s)
- Emmanuel Andrès
- a Departments of Internal Medicine, Medical Clinic B , University Hospital of Strasbourg , Strasbourg , France.,b Referral Center of immune cytopenias , University Hospital of Strasbourg , Strasbourg , France
| | - Rachel Mourot-Cottet
- a Departments of Internal Medicine, Medical Clinic B , University Hospital of Strasbourg , Strasbourg , France.,b Referral Center of immune cytopenias , University Hospital of Strasbourg , Strasbourg , France
| |
Collapse
|
11
|
Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R, Andrès E. Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (≥75 years): A Monocentric Cohort Study of 61 Cases. Drugs Real World Outcomes 2016; 3:393-399. [PMID: 27747601 PMCID: PMC5127888 DOI: 10.1007/s40801-016-0091-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Little data is currently available in the literature on neutropenia and agranulocytosis in the elderly, and, to our knowledge, idiosyncratic drug-induced agranulocytosis is particularly poorly covered, or not at all. OBJECTIVE We herein describe the clinical picture and outcome of patients aged ≥75 years with established idiosyncratic drug-induced agranulocytosis. PATIENTS AND METHODS Data from 61 patients over 75 years old with idiosyncratic drug-induced agranulocytosis were retrospectively reviewed. All cases were extracted from a cohort study on agranulocytosis (n = 203) in the Strasbourg University Hospitals (Strasbourg, France), a referral center. RESULTS The mean age was 84.9 years (range 75-95), the gender ratio (F/M) was 2.4. Underlying diseases were present in 74 %. The most frequent causative drugs were antibiotics (43.8 %), antithyroid drugs (15.8 %), neuroleptic and anti-epileptic agents (12.3 %), and antiaggregant platelet agents (10.5 %). The primary clinical features during hospitalization included isolated fever (27.6 %), septicemia or septic shock (24.1 %), and pneumonia (20.7 %). The mean neutrophil count at nadir was 0.15 × 109/L (range 0-0.4). All febrile patients were treated with broad-spectrum antibiotics and 36 with hematopoietic growth factors. Outcome was favorable in 85.3 % of patients; nine patients died. Two elderly patients (3.3 %) died of uncontrolled septic shock relating to the depth of the neutropenia. Comparison of mortality between <75- and ≥75-year-old patients revealed a statistical difference: 4.2 % versus 14.8 % (p = 0.023). CONCLUSIONS Our study demonstrates that 30 % of idiosyncratic drug-induced agranulocytosis concerned elderly patients. Antibiotic, antithyroid, neuroleptic, anti-epileptic, and antiaggregant platelet agents are the primary causative drug classes. Idiosyncratic drug-induced agranulocytosis is typically serious in this frail population of elderly patients, with at least 50 % suffering from severe sepsis and with a mortality rate of approximately 15 %. Modern management of agranulocytosis may reduce the infection-related mortality (3.3 %).
Collapse
Affiliation(s)
- Rachel Mourot-Cottet
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France
| | - Frédéric Maloisel
- Department of Onco-Hematology, Strasbourg University Hospitals, Strasbourg, France
| | - François Séverac
- Department of Statistics, Strasbourg University Hospitals, Strasbourg, France
| | - Olivier Keller
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France
| | - Thomas Vogel
- Department of Geriatrics, Strasbourg University Hospitals, Strasbourg, France
| | | | - Jean-Christophe Weber
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France
| | - Georges Kaltenbach
- Department of Geriatrics, Strasbourg University Hospitals, Strasbourg, France
| | | | - Bernard Goichot
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France
| | - Jean Sibilia
- Department of Rheumatology, Strasbourg University Hospitals, Strasbourg, France
| | - Anne-Sophie Korganow
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France
| | - Raoul Herbrecht
- Department of Onco-Hematology, Strasbourg University Hospitals, Strasbourg, France
| | - Emmanuel Andrès
- Department of Internal Medicine, Strasbourg University Hospitals, Strasbourg, France.
- Service de Médecine Interne, Diabète et Maladies Métaboliques, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, 1 Place de l'Hôpital, 67 091, Strasbourg Cedex, France.
| |
Collapse
|
12
|
Medrano-Casique N, Tong HY, Borobia AM, Carcas AJ, Frías J, Ramírez E. Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatr Hematol Oncol 2016; 33:441-456. [PMID: 27922762 DOI: 10.1080/08880018.2016.1234523] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES A prospective evaluation of nonchemotherapy drug-induced agranulocytosis (DIA) cases, which are infrequent in the pediatric population. We characterize agranulocytosis cases and assess lab test differences between drug- and nondrug-induced agranulocytosis. METHODS Through our Prospective Pharmacovigilance Program from Laboratory Signals at Hospital we detected pediatric agranulocytosis cases from July 2007 to December 2010. This program estimates the incidence, drug causality, clinical features, outcomes of DIA pediatric cases, and assesses laboratory differences with respect to non-DIA. RESULTS We detected 662 agranulocytosis in 308 pediatric patients, of which 14 were caused by nonchemotherapy drugs. The incidence rate of DIA for 10,000 pediatric patients was 3.92 (Poisson 95% confidence interval 1.09-8.77); 78.6% of DIA cases occurred in patients younger than 3 years. The final outcome was recovery without sequela in all cases. The pharmacologic group most frequently implicated was antimicrobial drugs (11 drugs), 7 of which were beta-lactams. The drugs most frequently suspected were cefotaxime and vancomycin (3 cases each). We found 3 drugs (cloperastine, codeine, and enoxaparin) not previously described to induce DIA. Automatic linear modeling (n = 56, R2 = 45.2%) showed a significant inverse association with platelets (R2 = 17.5%), hemoglobin, and alanine transaminase, and a direct association with red cell distribution (R2 = 16.2%). A generalized linear model (Type III, n = 1188; DIA, n = 86; likelihood ratio chi-squared = 156.16) retained eosinophils (p <.001), platelets (p <.001), total serum proteins (p <.001), and hemoglobin (p =.039). CONCLUSIONS We found a higher incidence of DIA in children than previously described. Our findings also suggest an immune-mediated destruction or myeloid toxicity, possibly facilitated by an increase in drug exposure.
Collapse
Affiliation(s)
- Nicolás Medrano-Casique
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| | - Hoi Y Tong
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| | - Alberto M Borobia
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| | - Antonio J Carcas
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| | - Jesús Frías
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| | - Elena Ramírez
- a Department of Clinical Pharmacology , La Paz University Hospital, IdiPAZ, School of Medicine, Autonomous University of Madrid , Madrid , Spain
| |
Collapse
|
13
|
Hashmi HRT, Jabbour R, Schreiber Z, Khaja M. Benazepril-Induced Agranulocytosis: A Case Report and Review of the Literature. AMERICAN JOURNAL OF CASE REPORTS 2016; 17:425-8. [PMID: 27335175 PMCID: PMC4920103 DOI: 10.12659/ajcr.898028] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Patient: Male, 61 Final Diagnosis: Benazepril induced agranulocytosis Symptoms: Sepsis Medication: — Clinical Procedure: None Specialty: Critical Care Medicine
Collapse
Affiliation(s)
| | - Rami Jabbour
- Department of Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USA
| | - Zwi Schreiber
- Department of Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USA
| | - Misbahuddin Khaja
- Division of Pulmonary and Critical Care Medicine, Bronx Lebanon Hospital Center, Bronx, NY, USA
| |
Collapse
|
14
|
Abstract
BACKGROUND Despite the controversial international debate on the use of metamizole as a standard analgesic, the prescription figures for Germany have increased constantly during recent years. However, metamizole can lead to the rare and severe medical condition called agranulocytosis. MATERIALS AND METHODS Between January 2009 and January 2014, 5 patients with metamizole-induced agranulocytosis presented themselves at the Interdisciplinary Emergency Center of the University Clinic Bonn. According to their leading ENT symptoms, they were transferred to the otorhinolaryngological department. We retrospectively evaluated metamizole medication, all general patient data and previous diseases, as well as disease course and the respective therapies. RESULTS Within the scope of the different treatments--surgery after trauma (n=2), elective orthopedic surgery (n=2), tonsillitis treatment (n=1)--the patients (n=5; mean age 30 years) had made regular ambulant use of metamizole for several days or weeks (4-28 days, mean 16.8 days). Daily oral dose ranged from 625 to 2000 mg/d (mean 1500 mg/d). Subsequently, patients required treatment for clinical symptoms of agranulocytosis (e.g. tonsillitis with severe odynophagia and significantly reduced general condition). All patients were monitored in an intermediate or intensive care unit (3-14 days, mean 10 days). No patients died. DISCUSSION As our cases show, when using metamizole as a standard analgesic, the treating otolaryngologist should look for clinical symptoms of agranulocytosis and inform patients about possible adverse effects. We recommend strict indication setting, regular blood analyses during long-term medication and consideration of alternative analgesics (e.g. NSAR).
Collapse
|
15
|
Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol 2015; 71:1129-38. [PMID: 26169297 DOI: 10.1007/s00228-015-1895-y] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2015] [Accepted: 06/24/2015] [Indexed: 12/16/2022]
Abstract
PURPOSE In 1986, the risk of agranulocytosis prompted German authorities to restrict the indications for metamizole use. After an initial decline, prescriptions increased from <20 million defined daily doses in 1990 to >140 million in 2012. Concurrently, spontaneous reports of agranulocytosis increased from about 10 in 1990 to >50 in 2012. In this study, reports were analyzed to identify targets for risk minimization measures. METHODS Reports of suspected metamizole-induced agranulocytosis (neutrophils < 0.5 × 10(9) cells/l) between 1990 and 2012 were identified in the German spontaneous reporting database. Cases for which original reporting documents were available were eligible for analysis. Patient characteristics, indication, clinical course, and outcome were assessed. RESULTS One hundred sixty-one reports were analyzed. The mean age of the patients was 56.8 years (11-93) and 64.6 % were female. Off-label use was identified in about 25 % of cases. Neutrophils fell below 100/μl in 63 and intercurrent infections developed in 109 cases. Thirty-eight patients (23.6 %) died. In two thirds of the cases, agranulocytosis occurred within 6 weeks of permanent or intermittent metamizole treatment, in 30.5 % within 7 days, including 18 cases of immediate onset after the first or second administration. CONCLUSION The reported cases show severe clinical courses and are, to some extent, a result of off-label use. Due to the absence of individual risk factors and presence of variable onset patterns, risk minimization measures should focus on restricting use to defined clinical situations and providing concise risk information for patients and healthcare professionals.
Collapse
|
16
|
Ngo S, Benhamou Y, Armengol G, Sauvêtre G, Cailleux-Talbot N, Massy N, Buchonnet G, Lévesque H. [Agranulocytosis related to fluindione: A case report]. Rev Med Interne 2015; 37:58-61. [PMID: 26096756 DOI: 10.1016/j.revmed.2015.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Revised: 04/25/2015] [Accepted: 05/17/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION While in most countries warfarin is the preferred anti-vitamin K, fluindione, a molecule with a prolonged half-life remains largely prescribed in France. Some of its side effects, including immuno-allergic complications, remain poorly understood. CASE REPORT A 77-year-old woman presented with a febrile severe neutropenia of immunoallergic mechanism with a favourable outcome associated with fluindione, introduced 25 days earlier for the treatment of atrial fibrillation. CONCLUSION This rare side effect is a reminder of the importance of biological monitoring in the first weeks following the introduction of fluindione and key diagnostic elements and therapeutic aspects of iatrogenic agranulocytosis.
Collapse
Affiliation(s)
- S Ngo
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France.
| | - Y Benhamou
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - G Armengol
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - G Sauvêtre
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - N Cailleux-Talbot
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - N Massy
- Pharmacovigilance, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - G Buchonnet
- Hématologie biologique, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| | - H Lévesque
- Département de médecine interne, CHU Rouen, 1, rue de Germont, 76031 Rouen cedex, France
| |
Collapse
|
17
|
Medrano-Casique N, Tong HY, Borobia AM, Carcas AJ, Frías J, Ramírez E. Non-Chemotherapy-Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital. Basic Clin Pharmacol Toxicol 2015; 117:399-408. [DOI: 10.1111/bcpt.12418] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2015] [Accepted: 05/11/2015] [Indexed: 01/30/2023]
Affiliation(s)
- Nicolás Medrano-Casique
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| | - Hoi Y. Tong
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| | - Alberto M. Borobia
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| | - Antonio J. Carcas
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| | - Jesús Frías
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| | - Elena Ramírez
- Department of Clinical Pharmacology; La Paz University Hospital; IdiPAZ; School of Medicine; Autonomous University of Madrid; Madrid Spain
| |
Collapse
|
18
|
Farag S, Verschoor AJ, Bosma JW, Gelderblom H, Kerst JM, Sleijfer S, Steeghs N. Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. J Clin Pharmacol 2015; 55:920-5. [PMID: 25810235 DOI: 10.1002/jcph.498] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Agranulocytosis is a rare but serious side effect of imatinib in gastrointestinal stromal tumor (GIST) patients. Imatinib is an inhibitor of the proto-oncogene tyrosine kinase (c-kit) and the first-line agent in patients with locally advanced and metastatic GIST. Little evidence is available on the management of this adverse event, and consensus-based guidelines are lacking. In this article, we describe 4 patients with agranulocytosis after starting imatinib. In addition, an overview of the available literature concerning the underlying mechanisms is given, and therapeutic strategies for overcoming this adverse event are discussed. In our experience it appears safe to restart imatinib after normalization of neutrophil count. In case of relapse of agranulocytosis, reintroduction combined with prednisolone, with treatment with granulocyte colony-stimulating factor or dose reduction can be considered.
Collapse
Affiliation(s)
- Sheima Farag
- Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Amsterdam, the Netherlands
| | - Arjan J Verschoor
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, the Netherlands
| | - Jacob W Bosma
- Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Amsterdam, the Netherlands
| | - Hans Gelderblom
- Leiden University Medical Center, Department of Clinical Oncology, Leiden, the Netherlands
| | - J Martijn Kerst
- Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Amsterdam, the Netherlands
| | - Stefan Sleijfer
- Erasmus MC - Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands
| | - Neeltje Steeghs
- Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Amsterdam, the Netherlands
| |
Collapse
|
19
|
Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol 2014; 11:243-57. [DOI: 10.1517/17425255.2015.985649] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
20
|
Pick AM, Nystrom KK. Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit? J Pharm Pract 2014; 27:447-52. [PMID: 25124379 DOI: 10.1177/0897190014546115] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Drug-induced agranulocytosis is a severe complication that has been implicated with most classes of medications. Medications such as clozapine, trimethoprim-sulfamethoxazole and methimazole have been more commonly associated with agranulocytosis than other agents. Although the pathogenesis isn't fully elucidated, it appears to be two-fold with a direct toxicity to the myeloid cell line and immune-mediated destruction. Patients may be asymptomatic at the time neutropenia is discovered or may present with more severe complications such as sepsis. In approximately 5% of cases drug-induced agranulocytosis may be fatal. Management of drug-induced agranulocytosis includes the immediate discontinuation of the offending medication, initiation of broad-spectrum antibiotics and consideration of the use of granulocyte colony-stimulating factors in high-risk patients.
Collapse
Affiliation(s)
- Amy M Pick
- School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska, NE, USA
| | - Kelly K Nystrom
- School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska, NE, USA
| |
Collapse
|
21
|
Drug-induced agranulocytosis in the Berlin case–control surveillance study. Eur J Clin Pharmacol 2013; 70:339-45. [DOI: 10.1007/s00228-013-1618-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Accepted: 11/20/2013] [Indexed: 12/18/2022]
|
22
|
Affiliation(s)
- W Khaliq
- Department of Medicine, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, MFL Bldg, West Tower 6th Floor, Baltimore, MD 21224, USA.
| | | | | | | | | |
Collapse
|
23
|
|
24
|
Abstract
All forms of thyroid diseases are much more frequently observed in women than men, although the reasons are still not completely elucidated.Hyperthyroidism is defined by elevated circulating free thyroid hormones. The prevalence is about 2 % in women and 0.2 % in men. The most frequent causes are various forms of thyroid autonomy in elderly women and Graves' disease, which occurs mostly in younger women.Hypothyroidism is defined by a lack of thyroid hormones. It is a common endocrine disorder caused by autoimmune thyroiditis (Hashimoto thyroiditis), iodine deficiency or following surgery or radioiodine therapy. Thyroxine requirements depend on fat-free mass and are, therefore, somewhat higher in males who are more often undersubstituted. In pregnancy lower TSH-reference ranges have to be considered and thyroid function should be monitored throughout pregnancy to avoid harm to the foetus caused by maternal thyroid dysfunctions. If overtreated women more often feature fractures, whereas males more often develop atrial fibrillation.
Collapse
Affiliation(s)
- Alois Gessl
- Department of Internal Medicine III, Medical University Of Vienna, Vienna, Austria
| | | | | |
Collapse
|
25
|
Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol 2011; 4:143-51. [PMID: 21495924 DOI: 10.1586/ehm.11.12] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE In this article, we report and discuss the clinical presentation and management of idiosyncratic drug-induced agranulocytosis (neutrophil count <0.5 × 10(9)/l). RESULTS/CONCLUSIONS Idiosyncratic drug-induced agranulocytosis remains a potentially serious adverse event owing to the frequency of severe sepsis with severe deep tissue infections (e.g., pneumonia), septicemia and septic shock in approximately two-thirds of all hospitalized patients. However, several prognostic factors have recently been identified that may be helpful in practice to identify 'susceptible' patients. Old age (>65 years), septicemia or shock, metabolic disorders such as renal failure and a neutrophil count below 0.1 × 10(9)/l are currently consensually accepted as poor prognostic factors. In this potentially life-threatening disorder, modern management with broad-spectrum antibiotics and hematopoietic growth factors (particularly granulocyte colony-stimulating factor) is likely to improve prognosis. Thus, with appropriate management, the mortality rate from idiosyncratic drug-induced agranulocytosis is currently approximately 5%.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine B, University Hospital of Strasbourg, 1 Porte de l'Hôpital, Strasbourg Cedex, France.
| | | | | | | | | | | |
Collapse
|
26
|
Abstract
Ciprofloxacin is a commonly used antibiotic for gastrointestinal and genitourinary tract infections with a considerably good safety profile. However, occasionally it may cause life-threatening complications. Two case reports of bone marrow depression and 1 case of thrombocytopenia due to ciprofloxacin therapy have been reported in literature. We report a case of bone marrow depression due to ciprofloxacin therapy for urinary tract infection in an otherwise healthy woman.
Collapse
|
27
|
Pontikoglou C, Papadaki HA. Idiosyncratic Drug-Induced Agranulocytosis: The Paradigm of Deferiprone. Hemoglobin 2010; 34:291-304. [DOI: 10.3109/03630269.2010.484791] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
28
|
Andrès E, Maloisel F, Zimmer J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol 2010; 150:3-8. [PMID: 20151980 DOI: 10.1111/j.1365-2141.2010.08104.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Drug-induced agranulocytosis (neutrophil count <0.5 x 10(9)/l) is a rare haematological complication with an incidence of no more than 10 cases per million inhabitants per year in Europe. Over the past few years there has been a steady decline in mortality rate, (currently at <5%), which can be partly explained by earlier recognition and the improved clinical management of associated intercurrent infections that may lead to severe sepsis if left untreated. The true impact of the use of haematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), on the decreased mortality rate remains unknown. Yet, most studies show that these molecules, especially G-CSF, reduce the duration of agranulocytosis, antibiotic course and length of hospital stay. Their use is particularly recommended in patients with poor prognostic factors, such as a neutrophil count <0.1 x 10(9)/l, age over 65 years, severe infection or multiple co-morbidities. In all cases, the drug responsible for causing the agranulocytosis must be discontinued and remain permanently contraindicated. The appropriate Medicines Regulatory Agency must also be notified of the adverse event.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine, B Clinic, University Hospital of Strasbourg, Strasbourg, France.
| | | | | |
Collapse
|
29
|
Abstract
Numerous medications and other xenobiotics are capable of producing adverse reactions (ADRs) affecting red cells, platelets or neutrophils. Occasionally, more than one blood element is affected simultaneously. As with all drug reactions, some side effects are a direct consequence of a known pharmacologic action of the drug and are dose-dependent; others occur sporadically and relatively independent of dose. The latter ("idiosyncratic") reactions are unpredictable and, in general, have no known underlying genetic basis. Many are antibody-mediated, as would be expected since cellular immune effector cells have little direct access to circulating blood cells. In this chapter, we will discuss idiosyncratic drug reactions affecting blood and blood forming tissues with an emphasis on those thought to be immune-mediated.
Collapse
Affiliation(s)
- Richard H Aster
- Blood Research Institute, Blood Center of Wisconsin, 2178 Watertown Plank Rd, Milwaukee, WI 53201, USA.
| |
Collapse
|
30
|
Abstract
Azithromycin (AZM) is widely used for respiratory tract infections and otitis media because of its activity against Haemophilus influenzae and atypical pathogens, and its ease of administration. Although leukopenia is the one of the most frequent AZM-related laboratory abnormalities in children, agranulocytosis has not been reported in adults. Here, we present the case of an 81-year-old man with agranulocytosis following AZM-treatment for acute otitis media. He developed febrile neutropenia and granulocyte colony-stimulating factor and cefepim were administered. All his symptoms and absolute neutrophil counts were recovered within 7 days after admission. Physicians must be vigilant in identifying drug-induced neutropenia in AZM-treated patients because early detection can decrease the severity and prevent mortality.
Collapse
|
31
|
Federici L, Weitten T, Alt M, Blaison G, Zamfir A, Audhuy B, Maloisel F, Andrès E. [Idiosyncratic drug-induced agranulocytosis]. Presse Med 2008; 37:1327-33. [PMID: 18644319 DOI: 10.1016/j.lpm.2008.03.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2008] [Accepted: 03/12/2008] [Indexed: 11/18/2022] Open
Abstract
Idiosyncratic drug-induced agranulocytosis is a potential adverse event of most drugs, rare but life-threatening. Its annual incidence does not exceed 10 cases per million population in Europe and has remained stable over the past two decades. Its pathogenesis is poorly understood. The principal drugs associated with it are antithyroid drugs, antibiotics including trimethoprim, sulfamethoxazole, and beta-lactamines, ticlopidine, sulfasalazine and dipyrone. Clinical presentation is highly variable but a severe infection is observed in more than one third of cases. Poor prognostic factors include a neutrophil count under 100/mm(3), age > 65 years, septicemia or shock, and severe comorbidity. Improvement in the management of infectious complications and the use of hematopoietic growth factors in severe cases helps explain that mortality rate has fallen to less than 5%.
Collapse
Affiliation(s)
- Laure Federici
- Service de médecine interne, Hôpital Pasteur, F-68000 Colmar, France
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Andrès E, Federici L, Weitten T, Vogel T, Alt M. Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis. Expert Opin Drug Saf 2008; 7:481-9. [DOI: 10.1517/14740338.7.4.481] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
33
|
Ibáñez L, Sabaté M, Ballarín E, Puig R, Vidal X, Laporte JR. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis. Pharmacoepidemiol Drug Saf 2008; 17:224-8. [DOI: 10.1002/pds.1542] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
34
|
|
35
|
Abstract
Acute agranulocytosis is a rare, potentially life-threatening condition, which is attributable to drugs in > 70% of cases. Agranulocytosis is characterised by a peripheral neutrophil count < 0.5 x 10(9)/l. It often manifests with a severe sore throat, but isolated fever, pneumonia or septicaemia are not uncommon. Agranulocytosis may be caused by many drugs. High-risk drugs include antithyroid drugs, clozapine, ticlopidine, sulfasalazine, dipyrone, trimethoprim/sulfamethoxazole, carbamazepine and probably rituximab. Suspect drugs should be stopped immediately. In febrile patients, blood cultures and, where indicated, site-specific cultures should be obtained and treatment with empirical broad spectrum antibiotics started. Haematopoietic growth factors should be considered in patients with poor prognostic factors (e.g., a neutrophil count < 0.1 x 10(9)/l), severe clinical infection or severe underlying disease or comorbidity. Case fatality has decreased to ~ 5% in recent years, probably owing to improved intensive care treatment and increased alertness of physicians to this severe adverse reaction.
Collapse
Affiliation(s)
- Edeltraut Garbe
- University Professor of Clinical Epidemiology, Bremen Institute for Prevention Research and Social Medicine, Bremen, Germany.
| |
Collapse
|
36
|
Andrès E, Zimmer J, Affenberger S, Federici L, Alt M, Maloisel F. Idiosyncratic drug-induced agranulocytosis: Update of an old disorder. Eur J Intern Med 2006; 17:529-35. [PMID: 17142169 DOI: 10.1016/j.ejim.2006.07.012] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2006] [Accepted: 07/13/2006] [Indexed: 11/25/2022]
Abstract
In this paper, we review the literature on idiosyncratic drug-induced agranulocytosis, a rare but life-threatening potential adverse event of most drugs. Articles were identified through MEDLINE searches (1966-2005). Additional references were localized through a review of textbooks on hematology and internal medicine, and information gleaned from international meetings. Additional unpublished data from our cohort with drug-induced agranulocytosis at the University Hospital of Strasbourg, France, were also considered. Searches were done using the following key words: "agranulocytosis", "drug-induced agranulocytosis", and "idiosyncratic agranulocytosis" and were restricted to: English- and French-language, human subjects, clinical trial, review, and guidelines. All of the papers and abstracts were reviewed by at least two senior researchers who selected the data used in the study. What we found is that, over the last 20 years, the incidence of idiosyncratic drug-induced agranulocytosis has remained stable - 2.4-15.4 cases per million - despite the emergence of new causative drugs, mainly antibiotics, antiplatelet agents, and antithyroid drugs. To date, drug-induced agranulocytosis remains a serious adverse event due to the frequency of severe sepsis with severe deep infections (such as pneumonia), septicemia, and septic shock in about two-thirds of all patients. In this setting, old age (>65 years), septicemia or shock, metabolic disorders such as renal failure, and a neutrophil count below 0.1x10(9)/L are poor prognostic factors. Nevertheless, with appropriate management using pre-established procedures, with intravenous broad-spectrum antibiotic therapy, and hematopoietic growth factors, the mortality rate is currently around 5%. Given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, health care professionals should be aware of this adverse event and its management.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine, University Hospital of Strasbourg, France
| | | | | | | | | | | |
Collapse
|
37
|
Andrès E, Maloisel F. Agranulocytoses médicamenteuses idiosyncrasiques. Rev Med Interne 2006; 27:209-14. [PMID: 16043267 DOI: 10.1016/j.revmed.2005.06.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2005] [Revised: 05/30/2005] [Accepted: 06/08/2005] [Indexed: 11/24/2022]
Abstract
BACKGROUND Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs. CURRENT DATA Idiosyncratic drug-induced agranulocytosis is characterized by a neutrophil count <0.5x10(9)/l, in serious forms <0,1x10(9)/l that currently occurs especially in association with antibiotics, antithyroid drugs ant ticlopidine (>60% of the incriminated drugs). The overall incidence of idiosyncratic agranulocytosis ranges from 2.4 to 15.4 cases per million patients exposed to drugs per year. Although patients experiencing idiosyncratic agranulocytosis may be asymptomatic (50%), the severity of the neutropenia usually leads to severe sepsis: fever of unknown origin, septicemia, septic shock or localized documented infections such as sore throat, various cutaneous infections or pneumonia. Nevertheless, the mortality rate of idiosyncratic agranulocytosis is now around 5% with appropriate management. PERSPECTIVES In the future, management of drug-induced agranulocytosis may include pre-established procedures using in critically situations, broad-spectrum antibiotic therapy and hematopoietic growth factors (G-CSF).
Collapse
Affiliation(s)
- E Andrès
- Service de Médecine Interne, Clinique Médicale B, Hôpitaux Universitaires de Strasbourg, France.
| | | |
Collapse
|
38
|
Hehn M, Labrune O, Degouy A, Duchene F, Laroche M, Maloisel F, Simon G, Kantelip JP. Agranulocytose sous loxapine chez une personne âgée : étude d’un cas. Therapie 2004; 59:561-4. [PMID: 15648311 DOI: 10.2515/therapie:2004096] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
39
|
Andrès E, Noel E, Maloisel F. Long-term outcome of patients treated with hematopoietic growth factors for idiosyncratic drug-induced agranulocytosis. Am J Med 2004; 116:354. [PMID: 14984824 DOI: 10.1016/j.amjmed.2003.08.026] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Andrès E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F. Life-Threatening Idiosyncratic Drug-Induced Agranulocytosis in Elderly Patients. Drugs Aging 2004; 21:427-35. [PMID: 15132711 DOI: 10.2165/00002512-200421070-00002] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Agranulocytosis is a life-threatening disorder in any age, but particularly so in elderly patients who are receiving, on average, a larger number of drugs than younger patients. Drug-induced agranulocytosis still remains a rare event, with an annual incidence rate of approximately 3-12 cases per million population. This disorder frequently occurs as an adverse reaction to drugs, particularly antibacterials, antiplatelet agents, antithyroid drugs, antipsychotics or antiepileptic drugs, and NSAIDs. Although patients experiencing drug-induced agranulocytosis may initially be asymptomatic, the severity of the neutropenia usually translates into the onset of severe sepsis that requires intravenous broad-spectrum antibacterial therapy. In this setting, haematopoietic growth factors have been shown to shorten the duration of neutropenia. Thus, with appropriate management, the mortality rate of idiosyncratic drug-induced agranulocytosis is now 5-10%. However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.
Collapse
Affiliation(s)
- Emmanuel Andrès
- Department of Internal Medicine, Hôpitaux Universitaires of Strasbourg, Strasbourg, France.
| | | | | | | | | | | |
Collapse
|